The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
 
Michael J. Jelinek
No Relationships to Disclose
 
Nathan R. Foster
No Relationships to Disclose
 
Alexander J. Zoroufy
No Relationships to Disclose
 
Jonas A. De Souza
No Relationships to Disclose
 
Gary K. Schwartz
Honoraria - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics
Consulting or Advisory Role - BioMotiv; Bionaut Labs; Champions Oncology; Daiichi Sankyo; DarwinHealth; Human Longevity, Inc; Karyopharm Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Pamela N. Munster
Stock and Other Ownership Interests - OncoSec (I)
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
 
Tanguy Y. Seiwert
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Innate Pharma; Jounce Therapeutics; Lilly; Merck; Merck Serono
Research Funding - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
 
Everett E. Vokes
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; Bayer; Biolumina; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Leidos Biomedical Research; Lilly; Merck; Novartis; Regeneron; Takeda; VentiRx